LncRNA Information
ID EL1058 Name PCGEM1 Aliases LINC00071; NCRNA00071; PCAT9
Species Homo sapiens Chromosome 2 Start site 192749845
End site 192776899 Chain plus Exon NO. 3
Assembly Ensembl Release 89 Class lincRNA NCBI accession NR_002769
Ensembl ENSG00000227418 Sequence


Disease
Disease Method Sample Expression pattern Dysfunction type Description PMID Source
prostate cancer microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) up-regulated N/A Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. 23728290 Lnc2Cancer
prostate cancer N/A N/A N/A expression PCGEM1 was originally discovered in a genome-wide gene expression screen as a cDNA sequence with prostate cancer overexpression and highly specific localization to glandular epithelial cells. 20951849 LncRNADisease
prostate cancer N/A N/A N/A regulation One of the earliest lncRNAs described in PCa, was PCGEM1(prostate cancer gene expression marker 1), a prostate-specific transcript encoded on 2q32 (40). One of the earliest lncRNAs described in PCa, was PCGEM1 (prostate cancer gene expression marker 1), a prostate-specific transcript encoded on 2q32 (40). 24146262 LncRNADisease
prostate cancer N/A N/A N/A regulation High-risk and predictive marker Oncogene 24373479 LncRNADisease
prostate cancer N/A N/A N/A N/A PCGEM1, PCA3 (prostate cancer antigen 3, known also as DD3, differential display code 3) and PCNCR1 (prostate cancer ncRNA 1) are involved in prostate cancer, while HULC (highly up-regulated in liver cancer) is involved with liver cancer. 24667321 LncRNADisease
prostate cancer N/A N/A N/A regulation The focus of this Nature report13 is on two PCa-associated lncRNAs: PCGEM1 and PRNCR1. They cooperate in regulating the function of the male hormone receptor, the androgen receptor (AR), which plays central role in PCa onset and progression. AR pathway is activated in advanced CaPs including castration-resistant prostate cancer (CRPC). 24713835 LncRNADisease
prostate cancer Northern blot etc. cell line (LNCaP) up-regulated N/A A prostate-specific and prostate cancer-associated noncoding gene, PCGEM1 regulates apoptosis. 16569192 LncRNADisease Lnc2Cancer
prostate cancer qPCR etc. prostate cancer tissue up-regulated expression Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. 14724589 LncRNADisease Lnc2Cancer
prostate cancer qPCR etc. prostate cancer tissue up-regulated expression The biomarkers had sensitivities ranging from 91% to 100%. Clinical specificities evaluated with the BPH tissue were the following: hTERT mRNA (93%), DD3 mRNA (57%), Survivin (29%) and PCGEM1 (14%). 16515751 LncRNADisease Lnc2Cancer
prostate cancer qPCR etc. cell lines (PC-3, DU145 etc.) up-regulated Interaction Phytosterol inhibition of PCGEM1 and cell growth and the overexpression of caveolin-1, suggests that poor disease prognosis anchors on the ability of caveolin-1 to regulate downstream oncogene(s) and apoptosis genes. 19186008 LncRNADisease Lnc2Cancer
prostate cancer qPCR etc. prostate cancer tissue up-regulated expression Expression profiles of genes in CRPC support a role for the transcriptional activity of the PCGEM1. 20868494 LncRNADisease Lnc2Cancer
prostate cancer qPCR etc. prostate cancer tissue differential expression mutation We found a significantly decreased risk of PCa for rs6434568 AC and AC/AA genotype, as well as rs16834898 AC and AC/CC genotype, compared with the CC and AA genotypes, respectively. 23459097 LncRNADisease Lnc2Cancer
prostate cancer qPCR etc. cell lines (LNCaP) up-regulated N/A PCGEM1 overexpression is highly associated with prostate tumors. CGEM1 tumorigenic potential has been recently shown to be in part due to its ability to activate androgen receptor (AR). Here, we report a novel function of PCGEM1 that provides growth advantages for cancer cells by regulating tumor metabolism via c-Myc activation. PCGEM1 promotes glucose uptake for aerobic glycolysis, coupling with the pentose phosphate shunt to facilitate biosynthesis of nucleotide and lipid, and generates NADPH for redox homeostasis. 25512540 LncRNADisease Lnc2Cancer
prostate cancer qPCR, Northern blot, FISH, ISH etc. prostate cancer tissue, cell lines (LNCaP, DU145, PC-3CaP etc.) up-regulated expression PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. 11050243 LncRNADisease Lnc2Cancer
prostate cancer qPCR, RIP etc. prostate cancer tissue,cell lines (LNCaP, LNCaP-cds1, LNCaP-cds2, CWR22Rv1 etc.), tissues (prostate tumour tissues) up-regulated expression Here we report that two lncRNAs highly overexpressed in aggressive prostate cancer, PRNCR1 (also known as PCAT8) and PCGEM1, bind successively to the androgen receptor and strongly enhance both ligand-dependent and ligand-independent androgen-receptor-mediated gene activation programs and proliferation in prostate cancer cells. 23945587 LncRNADisease Lnc2Cancer
prostate cancer RNA-seq, qRT-PCR N/A N/A N/A not implicated in castration resistant prostate cancer. 24727738
prostate cancer RT-PCR, luciferase reporter assay, MTT assay and flow cytometry, transwell assays LNCaP cells and noncancerous RWPE-1 prostate cells, (nu/nu) mouse model up-regulated interaction We demonstrate a reciprocal negative control relationship between PCGEM1 and miR-145 that regulates both LNCaP cell proliferation and nu/nu PCa tumor growth. 25200485
 


Function (not disease relevant)
Methods Sample/condition Expression pattern Dysfunction type Description PMID Source
N/A osteoarthritic human synoviocytes up-regulated interaction Exogenous overexpression of PCGEM1 inhibited apoptosis, induced autophagy, and stimulated the proliferation of human synoviocytes. The increased expression of PCGEM1 in human synoviocytes also suppressed the expression of miR-770. Transfection of the miR-770 precursor resulted in reduced proliferation, and induced apoptosis of human synoviocytes. This effect of miR-770 expression was reversed by co-introduction of PCGEM1. PCGEM1 act as sponge lncRNA for miR-770 that regulates proliferation/apoptosis and autophagy, and suggest PCGEM1 as possible target for OA therapy. 26340084
 


Interaction
Interaction target Level of interaction Type of interaction Description PMID Source
miR-145 RNA-RNA regulation Downregulation of PCGEM1 expression in LNCaP cells increased expression of miR-145, while overexpression of miR-145 decreased PCGEM1 expression. Transfection of the miR-145 expression vector and siRNA PCGEM1 inhibited tumor cell proliferation, migration, and invasion, and induced early apoptosis both in vitro. In contrast, there was no effect on RWPE-1 cells. 25200485
miR-770 RNA-RNA binding Target validation showed a direct binding between PCGEM1 and miR-770. PCGEM1 act as sponge lncRNA for miR-770 that regulates proliferation/apoptosis and autophagy, and suggest PCGEM1 as possible target for OA therapy. 26340084